附錄99.1

aytu biopharma報告了2024財政年度和第四季度的業務和財務結果

全年財政2024年度的綜合淨收入為8100萬美元；處方藥物業務部門的淨收入為6520萬美元

2024財政年度整年ADHD產品組合的淨營業收入較2023財政年度增長23%。

整個2024財政年度調整後的息稅折舊及攤銷前利潤(EBITDA)¹ 改善至920萬美元，較2023財政年度增加570萬美元

2024年6月30日，現金余額為2000萬美元

公司預期到2025財年，處方藥品部門的網絡營業收入和調整後的EBITDA將從目前水平增長。

公司將於今天9月26日下午4:30（美東時間）舉行電話會議和網絡廣播。

丹佛, 科羅拉多州 / 九月二十六日, 2024 Aytu BioPharma，Inc.（簡稱“公司”或“Aytu”）（納斯達克: AYTU），一家專注於商業化新型治療藥品的製藥公司，今天宣布了2024財政年度和第四季度的營運和財務結果。

2024財政年度全年要點

2024財政第四季要點

管理層討論

「在2024財政年度，我們繼續成功地將Aytu重新定位為一家專注於商業化新處方藥品的增長型專業藥品公司。在過去的一年裡，我們成功地減少了我們的消費業務，並隨後宣布出售，該業務於2024年7月完成。我們更加專注於我們高毛利的處方藥品業務，再加上成功實施了許多節約成本的措施，使得2024財政年度的調整後稅前息稅折舊前(EBITDA)達到920萬美元，相比於2023財政年度的350萬美元，提高了162%」，Aytu的首席執行官Josh Disbrow評論道。「更令人印象深刻的是，僅僅兩年前，我們的調整後EBITDA是負的2150萬美元，突顯出過去兩年超過3億美元的正向變化。展望未來，我們將繼續專注於推動處方增長，並利用我們商業平台的獨特能力，包括Aytu RxConnect。這個獨特計畫透過透明和可預測的藥品定價，為患者和醫療提供者提供極大的好處，推動未來收入增長和效率。」

在我們的處方營業收入部門，我們的ADHD組合淨營業收入全年增加了23％，並在財政年度下半年出現了8％的年度增長。此外，我們的兒童組合仍受到2023年9月發生的支付者變更的影響，但我們仍堅信兒童組合將從目前的水平中重新回歸增長。我們已實施了多項商業倡議，讓我們相信可以在全兒童組合範圍內恢復增長模式。我們看到這些增長倡議正在產生早期動力，因為自2024年7月1日至2024年9月25日，兒童產品的出貨量增加了115％。我們仍專注於推動處方需求，改進整個組合的覆蓋範圍和病人訪問，我們完全預期從2024財政年度水平看到處方營業收入部門淨營業收入和調整後EBITDA在財政2025年度全年增長。

「我們實施的戰略和運營措施使我們能夠保持強勢的現金儲備，截至財政年度結束時超過2000萬美元。這項成功的執行獲得了積極的財務認可，並從行使了部分認股權證中獲得了350萬美元的收益，其中一部分被用作資本來源，用於償還我們現有的授信貸款，以持續加強我們的資產負債表。我們還成功地對我們現有的授信貸款進行了再融資，在第四季度以對公司更有利的條件延長了我們的循環信貸額度。我們相信，通過對現金流量和盈利的戰略重點，我們將繼續通過營業收入增長和底線改善進一步增強公司的財務概況。」

非核心業務更新

公司於2023年6月宣布，已實施一項專注於其處方藥業務的戰略命令，以推動長期股東價值。公司已為2024財年和2023財年，以及過去九個報告季度中的八個報告季度的處方藥業務實現正調整後的EBITDA正值，不包括消費部門和管線研發（「處方藥業務」）。這種專注於處方藥業務的做法，是繼2024年7月成功完成消費部門的逐漸退出和出售後的成果。

強調盈利能力的目標最初始於2022年10月宣佈無限期暫停所有管線臨床開發項目，以最小化研發支出，直到公司能夠用內部產生的現金流或通過戰略合作伙伴基金支持這些努力。 在2023財年，消費健康板塊貢獻了-360萬美元的調整後EBITDA，管線項目貢獻了-260萬美元的調整後EBITDA，而公司的處方藥業務貢獻了970萬美元的調整後EBITDA。到2024財年，公司的處方藥業務貢獻了1080萬美元的調整後EBITDA。

《修訂和重新制定的2020年The Aaron's Company, Inc.股權和激勵計劃》，（參考到2024年5月16日提交給美國證券交易委員會的S-8表格附註4.3）。

⁽¹⁾其他包括已停產或優先級降低的產品。

全年度2024財務業績

全年2024財政年度營業收入為8100萬美元，較上一年期間的10740萬美元下降。此變動主要反映公司正在逐步淘汰消費業務部門，作為將業務專注於處方藥品部門的戰略要求的一部分，以提高長期股東價值。

Net revenue from the Rx Segment for the full year of fiscal 2024 was $65.2 million compared to $73.8 million in the prior year period. The ADHD Portfolio (Adzenys XR-ODT® and Cotempla XR-ODT®) experienced a 23% increase in net revenue to $57.8 million for full year fiscal 2024, compared to the prior year period. The Pediatric Portfolio (Karbinal® ER, Poly-Vi-Flor® and Tri-Vi-Flor®) net revenue decreased to $7.3 million largely due to payor changes that impacted prescriptions. Pediatric Portfolio unit shipments have increased 115% from July 1, 2024, through September 25, 2024.

Net revenue from the Consumer Health Segment was $15.8 million for full year fiscal 2024, a decrease of 53% over the same period last year. As previously announced, the Company completed the wind down and divestiture of its Consumer Health Segment in July of 2024 and expects that discontinuing this segment will improve operating cash flows and drive long-term stockholder value.

Consolidated gross profit was $54.6 million, or 67% of net revenue, for full year fiscal 2024, compared to $66.6 million, or 62% of net revenue, in the same period last year. Gross profit margin for the Rx Segment was 75% for full year fiscal 2024, compared with 71% in the prior year period.

Operating expenses, excluding amortization of intangible assets, restructuring costs, impairment expense and gain from contingent consideration, were $52.3 million for full year fiscal 2024 compared to $74.2 million in the prior year period. The decrease was a result of reduced Consumer Health spending and improved operational efficiencies.

Loss from operations for full year fiscal 2024 was $5.3 million compared to $17.1 million in the prior year period.

Net loss for full year fiscal 2024 was $15.8 million, or $2.86 net loss per share, compared to a $17.1 million net loss, or $5.11 net loss per share, in the prior year period. The fiscal 2024 full year results were impacted by $2.4 million of restructuring costs and $0.7 million of inventory impairment associated with the previously announced wind down of the Consumer Health Segment and Grand Prairie, Texas manufacturing facility as well as $4.4 million of derivative warrant liabilities loss due primarily to the increase in the Company’s stock price, $0.6 million loss on extinguishment of debt, and $1.8 million of income tax expense.

Consolidated adjusted EBITDA was $9.2 million for full year fiscal 2024, compared to $3.5 million in the prior year period, a $5.7 million increase. Adjusted EBITDA for the Rx Business was $10.8 million for full year fiscal 2024, compared to $9.7 million in the prior year period, a $1.2 million increase.

Cash and cash equivalents at June 30, 2024, were $20.0 million compared to $23.0 million at June 30, 2024.

Q4 Fiscal 2024 Financial Results

Net revenue for the fourth quarter of fiscal 2024 was $18.0 million, compared to $30.7 million for the prior year period.

Net revenue from the Rx Segment in the fourth quarter of fiscal 2024 was $14.6 million compared to $23.3 million in the prior year period. The ADHD Portfolio (Adzenys XR-ODT® and Cotempla XR-ODT®) experienced a 13% decrease in net revenue to $13.8 million in the fourth quarter of fiscal 2024, compared to the prior year period, largely as a result of normalization of the ADHD market supply chain. Net revenue for the ADHD Portfolio increased 8% to $26.1 million in the second half of fiscal 2024 versus $24.1 million in the second half of fiscal 2023. This net revenue growth was achieved despite the ADHD market supply chain normalization that occurred in the second half of 2024. The Pediatric Portfolio (Karbinal® ER, Poly-Vi-Flor® and Tri-Vi-Flor®) net revenue decreased to $0.8 million largely due to payor changes that impacted prescriptions. Growth of the ADHD Portfolio and Pediatric Portfolio is expected in fiscal 2025. Pediatric Portfolio unit shipments have increased 115% from July 1, 2024, through September 25, 2024.

Net revenue from the Consumer Health Segment was $3.4 million in the fourth quarter of fiscal 2024, a decrease of 54% over the same quarter last year. As previously announced, the Company completed the wind down and divestiture of its Consumer Health Segment in July of 2024 and expects that discontinuing this segment will improve operating cash flows and drive long-term stockholder value.

Consolidated gross profit was $11.9 million, or 66% of net revenue, in the fourth quarter of fiscal 2024, compared to $18.6 million, or 60% of net revenue, in the same quarter last year. Gross profit margin for the Rx Segment was 76% in the fourth quarter of fiscal 2024, compared with 75% in the prior year period.

Operating expenses, excluding amortization of intangible assets, restructuring costs, impairment expense and gain from contingent consideration, were $12.1 million in the fourth quarter of fiscal 2024 compared to $14.6 million in the prior year period. The decrease was a result of reduced Consumer Health spending and improved operational efficiencies.

Loss from operations during the fourth quarter of fiscal 2024 was $3.7 million compared to income from operations of $0.2 million in the prior year period.

Net loss during the fourth quarter of fiscal 2024 was $4.6 million, or $0.82 net loss per share, compared to a $2.5 million net loss, or $0.59 net loss per share, in the prior year period. The fiscal 2024 fourth quarter results were impacted by $2.1 million of restructuring costs and $0.7 million of inventory impairment associated with the previously announced wind down of the Consumer Health Segment and Grand Prairie, Texas manufacturing facility as well as $1.5 million of derivative warrant liabilities gain due primarily to the decrease in the Company’s stock price, $0.6 million loss on extinguishment of debt, and $0.7 million of income tax expense.

Consolidated adjusted EBITDA was $1.5 million in the fourth quarter of fiscal 2024, compared to $7.7 million in the prior year period, a $6.2 million decrease resulting largely from the decrease in the Pediatric Portfolio net revenue. Adjusted EBITDA for the Rx Business was $2.0 million in the fourth quarter of fiscal 2024, compared to $8.3 million in the prior year period, a $6.2 million decrease.

Conference Call Details

Date and Time: Thursday, September 26, 2024, at 4:30 p.m. Eastern time.

Call-in Information: Interested parties can access the conference call by dialing (888) 506-0062 for United States callers or +1 (973) 528-0011 for international callers and using the participant access code 216512.

Webcast Information: The webcast will be accessible live and archived at https://www.webcaster4.com/Webcast/Page/2142/51231, and accessible on the Investors section of the Company’s website at https://investors.aytubio.com/ under Events & Presentations.

Replay: A teleconference replay of the call will be available until October 10, 2024, at (877) 481-4010 for United States callers or +1 (919) 882-2331 for international callers and using replay access code 51231.

About Aytu BioPharma, Inc.

Aytu is a pharmaceutical company focused on commercializing novel therapeutics. The Company’s prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. To learn more, please visit aytubio.com.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”). All statements other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such as “may,” “will,” “should,” “forecast,” “could,” “expect,” “suggest,” “believe,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. All statements other than statements of historical facts contained in this presentation, are forward-looking statements. These statements are predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others, risks associated with: the Company’s plans relating to the Company’s ability to efficiently wind down the Consumer Health Segment, the Company’s ability to complete the manufacturing transfer of Adzenys XR-ODT® and Cotempla XR-ODT®, the Company’s overall financial and operational performance, potential adverse changes to the Company’s financial position or our business, the results of operations, strategy and plans, changes in capital markets and the ability of the Company to finance operations in the manner expected, risks relating to gaining market acceptance of our products, our partners performing their required activities, our anticipated future cash position, regulatory and compliance challenges and future events under current and potential future collaborations. We also refer you to (i) the risks described in “Risk Factors” in Part I, Item 1A of our most recent Annual Report on Form 10‑K and in the other reports and documents it files with the United States Securities and Exchange Commission.

Footnote 1

Aytu uses the term adjusted EBITDA, which is a term not defined under United States generally accepted accounting principles (“U.S. GAAP”). The Company uses this term because it is a widely accepted financial indicator utilized to analyze and compare companies on the basis of operating performance. The Company believes that presenting adjusted EBITDA by certain categories allows investors to evaluate the various performance of these categories. The Company’s method of computation of adjusted EBITDA may or may not be comparable to other similarly titled measures used by other companies. We believe that net income (loss) is the performance measure calculated and presented in accordance with U.S. GAAP that is most directly comparable to adjusted EBITDA. See below for a reconciliation of net income (loss) to adjusted EBITDA.

Contacts for Investors

Mark Oki, Chief Financial Officer

Aytu BioPharma, Inc.

moki@aytubio.com

Robert Blum or Roger Weiss

Lytham Partners

aytu@lythampartners.com

Aytu BioPharma, Inc.

Consolidated Statements of Operations

(in thousands, except share and per share data)

Aytu BioPharma, Inc.

Consolidated Balance Sheets

(in thousands, except share data)

Aytu BioPharma, Inc.

Reconciliation of Net Loss to Adjusted EBITDA - Twelve Months Ended

(in thousands)

Aytu BioPharma, Inc.

Reconciliation of Net Income (Loss) to Adjusted EBITDA - Three Months Ended

(in thousands)